Experts warn that Trump's new tariffs on imports could drive up health care costs in the US by increasing the costs of pharmaceuticals and medical supplies. The US heavily relies on pharmaceutical imports, with China being a major producer of active pharmaceutical ingredients (APIs). The tariffs could exacerbate drug shortages and increase healthcare costs, especially for generic drug manufacturers who may exit the market due to financial strain. Industry groups are pushing for tariff exemptions and policies that encourage domestic manufacturing.

The Trump administration announced new tariff plans on April 2, imposing a 10% universal tariff on imported goods starting April 5. Reciprocal tariffs on certain countries are set to begin on April 9, with exemptions for pharmaceuticals, semiconductors, and copper. The 'de minimis loophole' for Chinese imports was also closed. Healthcare professionals are concerned about the impact on medical supplies and pharmaceutical innovation, potentially leading to higher costs and job losses.

The article discusses the international response to the earthquake that struck Myanmar and Thailand, focusing on the severe shortage of medical supplies in Myanmar. The death toll has risen to 1,644 with 3,408 injured and 139 missing. Countries and organizations have provided significant aid, including medical supplies and personnel.